Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: Open-End Fund
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: Global

Danske Invest-Bioteknologi Fund

+ Add to Watchlist

DANIBIO:DC

283.1000 DKK 3.5000 1.25%

As of 11:00:00 ET on 05/22/2015.

Snapshot for Danske Invest-Bioteknologi Fund (DANIBIO)

Open: 279.6000 High - Low: 283.3000 - 277.6000 Primary Exchange: Copenhagen
Volume: 13,017 52-Week Range: 173.5000 - 372.7000 Beta vs BTK: 1.0242

ETF Chart for DANIBIO

No chart data available.
  • DANIBIO:DC 283.1000
  • 1D
  • 1M
  • 1Y
279.6000
Interactive DANIBIO Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for DANIBIO

Danske Invest Bioteknologi Fund is an open-end fund registered in Denmark. The Fund's objective is capital appreciation, and to outperform NASDAQ's biotech-index(NBI). The Fund invests worldwide in equity of biotechnology companies, and companies closely related to the biotechnology sector.

Inception Date: 2000-05-26 Telephone: 45-3333-7171
Managers: -
Web Site: www.danskeinvest.dk

Fundamentals for DANIBIO

NAV (on 2015-05-22) 282.0300
Assets (M) (on 2015-04-30) 1,227.2480
Shares out (M) 0.00
Market Cap (M) 0.00
% Premium 0.38
Average 52-Week % Premium 0.9975
Fund Leveraged N

Dividends for DANIBIO

Dividend Type Income
Dividend Frequency Annual
Last Dividend Net (on 2015-04-23) 62.1000
Dividend Yield (ttm) 21.94%

Performance for DANIBIO

1-Month +18.70% 1-Year +97.95%
3-Month +10.33% 3-Year +45.87%
Year To Date +28.68% 5-Year +33.23%
Expense Ratio 1.50

Top Fund Holdings for DANIBIO

Filing Date: 03/31/2015
Name Position Value % of Total
Intercept Pharmaceuticals Inc 44,145 86,600,620 5.624%
Pharmacyclics Inc 45,683 81,333,474 5.282%
Celldex Therapeutics Inc 327,625 63,514,601 4.125%
BioMarin Pharmaceutical Inc 66,832 57,933,768 3.762%
Incyte Corp 89,443 57,027,690 3.703%
United Therapeutics Corp 47,144 56,547,241 3.672%
Novavax Inc 976,491 56,173,738 3.648%
Biogen Inc 18,842 55,340,865 3.594%
Medivation Inc 61,295 55,031,320 3.574%
Charles River Laboratories Int 97,518 53,785,199 3.493%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil